Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

Inclusion Criteria: * Be male or female over 18 years of age * Be a Patient with a previous confirmed diagnosis of Crohn´s disease an Ulcerative Colitis * Previous treated with original Adalimumab for at least 6 months with regular maintenance dose (40 mg every 15 days) and in clinical and biological remission. * Patients under treatment with intensified Adalimumab (40mg every 7 days or 80mg every 7 days) to maintain clinical and biological remission for at least 6 months. * Patients with oral mesalazine with a stable dose for more than 30 days. * Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time\> 60 days. * Patients may be accepted with corticosteroids at the established doses: prednisone \<20mg / dl, budesonide \<9mg / dl. * Patients who have a tuberculosis (TB) study (Mantoux / QuantiFERONTB test) updated in the last two year, with a negative result. * Patient with serology hepatitis B and C, updated at the beginning of the treatment with Humira® * Sign an informed consent document indicating that he/she understands the purpose of, and procedures required for, the study and are willing to participate in the study. Exclusion Criteria: * Positive pregnancy test at the time of inclusion or during the follow-up period, as well as women who are breastfeeding * Patients with uncontrolled comorbidities, active cancer, diabetes mellitus, severe cardiovascular disease, obstructive pulmonary disease, serious active infections. * Patients with oral mesalazine initiated less than 30 days. * Patients with immunosuppressive therapy (methotrexate, azathioprine) with a minimum intake time of \<60 days. * Patient with original Adalimumab who do not meet a minimum of 6 months of stable dose (40 mg every 7 or 15 days) * Patient on corticosteroid therapy at doses: prednisone\> 20mg / dl, budesonide = 9mg / dl, or with IV corticoids within 14 days prior screening date. * Patients with mental disorders, alcohol / other substance abuse, or conditions that do not allow adherence to the study protocol. * Patients with active TB * Patients with defined Hepatitis B and C defined as: HBV: hepatitis B surface antigen (HbsAg) positive together with positive HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR). HCV: HCV ribonucleic acid (RNA) detectable in any patient with positive anti-HCV antibody (IgG)